REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
18/02/2025
Voltar para busca
Dado oficial do USPTO
POLYNAUT
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
18/02/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
14/01/2019
Data de registro
18/02/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
18/02/2020
Última transação
18/02/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
4
Tipo de titular
24
Localização do titular
HISTON, CAMBRIDGE, GB
Examinador
WILSON, MARYNELLE
Unidade examinadora
M40
Localização atual
TMO LAW OFFICE 113
Titulares e representantes
Titulares
SOMASERVE LIMITED
Somanautix Limited
Representantes
Ben Natter HAUG PARTNERS LLP
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals used in science; chemicals for encapsulatingmicroencapsulating and decapsulating other chemicals; chemicals for the protectiondeliverytransport and triggered or controlled release of other chemicals; chemicals for encapsulatingmicroencapsulating and decapsulating biologically active ingredients including enzymes and cells; reagents and diagnostic preparations for scientific or medical research useclinical or medical laboratory use in oncology; targeted diagnostic preparations for scientific or medical research useclinical or medical laboratory use in oncology
Classe 5
Pharmaceutical preparations for the treatment and prevention of infectiousautoimmuneviralmetabolicmusculoskeletalcardiovasculargenitourinarycentral nervous systemendocrinologicalimmunologicalobstetricalgynaecologicaloncologicalrespiratoryneurologicalgastrointestinalhormonaldermatological and psychiatric diseases and disorders; reagentsdiagnostics and therapeutic preparations for medical and veterinary use in oncology; therapeutic preparations for use in treating cancer in medical and veterinary patients; targeted medical and veterinary preparations for use in oncology; medical and veterinary preparations for use in chemotherapy and immunotherapy for the treatment and prevention of infectiousautoimmuneviralmetabolicmusculoskeletalcardiovasculargenitourinarycentral nervous systemendocrinologicalimmunologicalobstetricalgynaecologicaloncologicalrespiratoryneurologicalgastrointestinalhormonaldermatological and psychiatric diseases and disorders; medical and veterinary preparations for the delivery of compounds to the brain for the treatment and prevention of infectiousautoimmuneviralmetabolicmusculoskeletalcardiovasculargenitourinarycentral nervous systemendocrinologicalimmunologicalobstetricalgynaecologicaloncologicalrespiratoryneurologicalgastrointestinalhormonaldermatological and psychiatric diseases and disorders; medical and veterinary preparations for crossing the blood-brain barrier for the treatment and prevention of infectiousautoimmuneviralmetabolicmusculoskeletalcardiovasculargenitourinarycentral nervous systemendocrinologicalimmunologicalobstetricalgynaecologicaloncologicalrespiratoryneurologicalgastrointestinalhormonaldermatological and psychiatric diseases and disorders; medical and veterinary preparations for delivering reagentsdiagnostics and therapeutics across the blood-brain barrier for the treatment and prevention of infectiousautoimmuneviralmetabolicmusculoskeletalcardiovasculargenitourinarycentral nervous systemendocrinologicalimmunologicalobstetricalgynaecologicaloncologicalrespiratoryneurologicalgastrointestinalhormonaldermatological and psychiatric diseases and disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
20/01/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
20/01/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
20/01/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
30/12/2020
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
06/05/2020
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
05/05/2020
PRAM
POST REGISTRATION ACTION MAILED - SEC. 7
04/05/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
27/04/2020
ES7R
TEAS SECTION 7 REQUEST RECEIVED
21/03/2020
ES7R
TEAS SECTION 7 REQUEST RECEIVED
20/03/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
18/02/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/12/2019
PUBO
PUBLISHED FOR OPPOSITION
03/12/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/11/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/10/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
28/10/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
28/10/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
28/10/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
28/10/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/10/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/10/2019
ALIE
ASSIGNED TO LIE
07/10/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/10/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/04/2019
GNRT
NON-FINAL ACTION E-MAILED
03/04/2019
CNRT
NON-FINAL ACTION WRITTEN
03/04/2019
DOCK
ASSIGNED TO EXAMINER
27/03/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/02/2019
NWAP
NEW APPLICATION ENTERED
17/01/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace POLYNAUT ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.